NEUTRISCI TO COMPLETE SHARE SETTLEMENT
Vancouver, British Columbia – March 27, 2018 – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy, announces that it will issue 162,936 common shares, at a deemed price of $0.195 per share, in settlement of a territory licensing fee owing in connection with the global licensing agreement entered into with Lexaria Bioscience Corp. and announced on February 26, 2018. Completion of the share issuance is subject to the approval of the TSX Venture Exchange, and the shares will be subject to a four-month-andone-day statutory hold period following issuance.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
CEO & President
Tel: (403) 264-6320
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. NeutriSci is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.